Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases

Journal of Internal Medicine

Volumn 247, Issue 3, 2000, Pages 381-384

  Vaarala, Outi ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

2 glycoprotein I; Anticardiolipin antibodies; Atherosclerosis; Oxidized LDL; Prothrombin

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTHROMBIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; PHOSPHOLIPIDS;

EID: 0034073323     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00657.x     Document Type: Conference Paper

References (32)

1. 1 Puurunen M, Mänttäri M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-9.
2. 2 Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Tromb Vasc Biol 1997; 17: 3159-63.
3. 3 Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
4. 4 Sinisalo J, Paronen J, Mattila KJ, et al. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis, in press.
5. 5 Vaarala O. Alfthan G. Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-5.
6. 6 Amengual O, Atsumi T, Khamashta MA, Tinahones F. Hughes GR. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997; 36: 964-8.
7. 7 Cuadrado MJ, Tinahones F, Camps MT, et al. Antiphospholipid, anti-beta 2-glycoprotein 1 and anti-oxidized-low-density antibodies in antiphospholipid syndrome. Q J Med 1998; 91: 619-26.
8. 8 Vaarala O, Puurunen M, Lukka M, et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidised low-density lipoprotein. Clin Exp Immunol 1986; 104: 269-74.
9. 9 Hörkkö S, Miller E, Dudl E, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipid. J Clin Invest 1996; 98: 815-25.
10. 10 Palinski W, Ylä-Herttuala S. Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10: 325-35.
11. 11 Matsuura E, Katahira T, Igarashi Y, Koike T. β2-glycoprotein I bound to oxidatively modified lipoproteins could be targeted by anticardiolipin antibodies. Lupus 1994; 3: 314.
12. 12 Matsuda J, Gotoh M, Kawasugi K, Gohchi K, Tsukamoto M, Saitoh N. Negligible synergistic effect of beta2-glycoprotein I on the reactivity of antioxidized low-density lipoprotein antibody to oxidized low-density lipoprotein. Am J Hematol 1996; 52: 114-6.
13. 13 Tinahones FJ, Cuadrado MJ, Khamashta MA, et al. Lack of cross-reaction between antibodies to beta2-glycoprotein-1 and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br J Rheumatol 1998; 37: 746-9.
14. 14 Mizutani H, Kurata Y, Kosugi S, et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand White x BXSB) Fl mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arhtritis Rheum 1995; 38: 1382-8.
15. 15 Aho K, Vaarala O, Tenkanen L, et al. Antibodies binding to anionic phospholipids but not to oxidized low-density lipoprotein are associated with thrombosis in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 499-506.
16. 16 Lopes-Virella M, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997; 135: 161-70.
17. 17 George J, Afek A, Gilburd B, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-52.
18. 18 Freigang S, Hörkkö S, Miller E, Witzum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972-82.
19. 19 Vaarala O, Mänttäri M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7.
20. 20 Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus: a controlled prospective study. Am J Med 1996; 101: 381-6.
21. 21 Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28: 1660-5.
22. 22 Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992; 339: 451-3.
23. 23 Zsakiris DA, Marbet GA, Burkat F, Duckert F. Anticardiolipin antibodies and coronary heart disease. Eur Heart J 1992; 13: 1645-8.
24. 24 Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-73.
25. 25 George J, Afek A, Gilburd B, et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 1998; 98: 1108-15.
26. 26 Afek A, George J, Shoenfeld Y, et al. Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology 1999; 67: 19-25.
27. 27 George J, Harats D, Gilburd B, et al. Immunolocalization of β2-glycoprotein I (Apolipoprotein II) to human atherosclerotic plaques. Potential implications for lesion progression. Circulation 1999; 99: 2227-30.
28. 28 Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-9.
29. 29 Puurunen M, Mänttäri M, Manninen V, Palosuo T, Vaarala O. Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction. Br J Haematol 1998; 100: 374-9.
30. 30 Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5: 442-7.
31. 31 Iuliano L, Pratico D, Ferro D, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997; 90: 3931-5.
32. 32 Ames PR, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V, Anggard EE. Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost 1998; 79: 447-9.